NO930731L - kininogenase inhibitor - Google Patents

kininogenase inhibitor

Info

Publication number
NO930731L
NO930731L NO93930731A NO930731A NO930731L NO 930731 L NO930731 L NO 930731L NO 93930731 A NO93930731 A NO 93930731A NO 930731 A NO930731 A NO 930731A NO 930731 L NO930731 L NO 930731L
Authority
NO
Norway
Prior art keywords
amino acid
group
analog
amide
conformational
Prior art date
Application number
NO93930731A
Other languages
Norwegian (no)
Other versions
NO930731D0 (en
Inventor
Michael Szelke
David Michael Evans
David Michael Jones
Original Assignee
Ferring Peptide Research Partn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Peptide Research Partn filed Critical Ferring Peptide Research Partn
Publication of NO930731D0 publication Critical patent/NO930731D0/en
Publication of NO930731L publication Critical patent/NO930731L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Kininogenaseinhibitorer, som optimalt ikke overskrider størrelsen av et heksapeptid, represen-tert ved (II), hvor A og B = aminoacyl (omfattende aminoacylanalog) som er de samme eller forskjellige og danner en dipeptidgruppe hvor aminosyren A "har en terminalgruppe og er en hvilken som helst amino- eller iminosyrerest (men fortrinnsvis med D-konfigurasjon, og B er en lipofil aminosyrerest med D- eller L-konfigurasjon, men ikke prolin eller en prolinanalog, eller en konformasjonsanalog av nevnte dipeptidgruppe hvor peptidbindingen er erstattet med -CH-NH- ("redusert"), -CH(OH)-CH- ("hydroksy"), -CO-CH("keto"), -CHCH- ("hydrokarbon") eller en annen konformasjonsetterligning av peptidbindingen og i (III) skal sidekjeden Rvære sidekjeden i en basisk aminosyre eller aminosyreanalog (fortrinnsvis med L-konfigurasjon), og R være H eller lavere alkyl(0-0) eller C eller peptidbindingen omfattende -N(R)- er erstattet, hvilket farer til en konformasjonsetterligning som ovenfor; V = en bindingsøkende eller karbonylaktiverende gruppe, fortrinnsvis valgt fra H (når A eller B må være cykloheksylalanin, fortrinnsvis D dersom den er A eller L dersom den er B) eller alkyl (CCq) eller fluoralkyl (C-C); substituert oksymetylen; tiometylen; sulfoksymetylen; sulfonylmetylen; aminometylen; hydrazino-metylen; -CH-Het (hvor Het = en substituert eller usubstituert heterocyklus); substituert amino (men når den resulterende forbindelse er et sekundært alkylamid, må B ikke være fenylalanin); en aminosyregruppe eller dens ester eller amid; et karboksylisk sekundært amid eller primært amid, når B må være cykloheksylalanin eller adamantylalanin eller en annen svær lipofil, ikke-aromatisk aminosyre (ikke Ala Leu Ile Val Nva Met Nie Phe Tyr Trp Nal (1)); tertiært karboksamid; karboksyalkylgruppe eller dens ester eller amid eller aminoacylderivat.Quininogenase inhibitors, which optimally do not exceed the size of a hexapeptide, represented by (II), wherein A and B = aminoacyl (comprising aminoacyl analog) which are the same or different and form a dipeptide group where amino acid A "has a terminal group and is a any amino or amino acid residue (but preferably with D-configuration, and B is a lipophilic amino acid residue with D- or L-configuration, but not proline or a proline analog, or a conformational analog of said dipeptide group in which the peptide bond is replaced by -CH-NH - ("reduced"), -CH (OH) -CH- ("hydroxy"), -CO-CH ("keto"), -CHCH- ("hydrocarbon") or other conformational imitation of the peptide bond and in (III) the side chain R should be the side chain of a basic amino acid or amino acid analog (preferably with L-configuration), and R is H or lower alkyl (0-0) or C or the peptide bond comprising -N (R) - is replaced, leading to a conformational imitation which above; V = a binding search nd or carbonyl activating group, preferably selected from H (when A or B must be cyclohexylalanine, preferably D if it is A or L if it is B) or alkyl (Cqq) or fluoroalkyl (C-C); substituted oxymethylene; thiomethylene; sulfoxymethylene; sulfonylmethylene; aminomethylene; hydrazinomethylene; -CH-Het (wherein Het = a substituted or unsubstituted heterocycle); substituted amino (but when the resulting compound is a secondary alkylamide, B must not be phenylalanine); an amino acid group or its ester or amide; a carboxylic secondary amide or primary amide, when B must be cyclohexylalanine or adamantylalanine or another major lipophilic, non-aromatic amino acid (not Ala Leu Ile Val Nva Met Nie Phe Tyr Trp Nal (1)); tertiary carboxamide; carboxyalkyl group or its ester or amide or aminoacyl derivative.

NO93930731A 1990-09-07 1993-02-26 kininogenase inhibitor NO930731L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909019558A GB9019558D0 (en) 1990-09-07 1990-09-07 Enzyme inhibitors
PCT/GB1991/001479 WO1992004371A1 (en) 1990-09-07 1991-09-02 Kininogenase inhibitors

Publications (2)

Publication Number Publication Date
NO930731D0 NO930731D0 (en) 1993-02-26
NO930731L true NO930731L (en) 1993-05-07

Family

ID=10681831

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930731A NO930731L (en) 1990-09-07 1993-02-26 kininogenase inhibitor

Country Status (13)

Country Link
EP (1) EP0652893A1 (en)
JP (1) JPH06501461A (en)
AU (1) AU8438791A (en)
CA (1) CA2090858A1 (en)
FI (1) FI930946A (en)
GB (1) GB9019558D0 (en)
HU (1) HUT64084A (en)
IE (1) IE913120A1 (en)
MC (1) MC2313A1 (en)
NO (1) NO930731L (en)
PT (1) PT98885A (en)
WO (1) WO1992004371A1 (en)
ZA (1) ZA917096B (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103612D0 (en) * 1991-12-04 1991-12-04 Astra Ab NEW PEPTIDE DERIVATIVES
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
SE9301911D0 (en) * 1993-06-03 1993-06-03 Ab Astra NEW PEPTIDE DERIVATIVES
SE9301916D0 (en) * 1993-06-03 1993-06-03 Ab Astra NEW PEPTIDES DERIVATIVES
US5783563A (en) * 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
SE9404196D0 (en) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
US5696231A (en) * 1994-12-21 1997-12-09 Corvas International, Inc. N-substituted glycine derivatives as enzyme inhibitors
US6025472A (en) * 1994-12-21 2000-02-15 Corvas International, Inc. N-substituted glycine derivatives as enzyme inhibitors
CZ132798A3 (en) * 1995-10-30 1999-02-17 Smithkline Beecham Corporation Protease inhibitors
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
TWI238827B (en) 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
US6417161B1 (en) 1998-04-24 2002-07-09 3-Dimensional Pharmaceuticals, Inc. Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
YU42401A (en) 1998-12-14 2003-12-31 Ortho-Mcneil Pharmaceuticals Inc. Substituted heterociclic acyl-tripeptides useful as thrombin receptor modulators
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
EP1930021A3 (en) 1999-02-18 2008-06-18 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2003513924A (en) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
CN1416346A (en) 2000-03-21 2003-05-07 史密丝克莱恩比彻姆公司 Peotease inhibitors
GB0205527D0 (en) * 2002-03-08 2002-04-24 Ferring Bv Inhibitors
JP2006511452A (en) 2002-07-03 2006-04-06 バイオ サイエンス インターナショナル インコーポレイテッド Peptide containing aromatic D-amino acid and method of using the same
FR2846969A1 (en) * 2002-11-08 2004-05-14 Salles Jean Pierre New modified active agent derivatives with improved bioavailability comprising parent drug, e.g. anticancer agent, plus fluorinated hydrocarbon chain and recognition or hydrophilizing moiety
EP1736465A4 (en) 2004-03-31 2009-06-17 Ajinomoto Kk Aniline derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
IL239682B (en) 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd Benzylamine and 2-(aminomethyl)pyridine derivatives
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
RU2712621C2 (en) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Nitrogen-containing heterocyclic derivatives useful as plasma kallikrein inhibitor
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
TWI636047B (en) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 Heterocyclic derivatives
CN105683179B (en) 2013-08-14 2018-10-26 卡尔维斯塔制药有限公司 The inhibitor of plasma kallikrein
RU2728785C2 (en) 2014-10-06 2020-07-31 Кортексим, Инк. Inhibitors of lysine-specific gingipain
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
JP6877424B2 (en) 2015-11-09 2021-05-26 コーテクシーミー， インコーポレイテッド Inhibitor of arginine gingipain
KR20220107319A (en) 2016-05-31 2022-08-02 칼비스타 파마슈티컬즈 리미티드 Pyrazole derivatives as plasma kallikrein inhibitors
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
TWI787202B (en) 2016-09-16 2022-12-21 美商昆斯治療公司 Ketone inhibitors of lysine gingipain
CN107011217B (en) * 2017-03-24 2018-08-14 东华大学 A kind of fat-soluble 5-ALA derivative and its preparation method and application
CN107043338B (en) * 2017-03-24 2018-09-25 东华大学 A kind of 5-ALA derivative and its preparation method and application
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
HRP20220367T1 (en) 2017-11-29 2022-05-27 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
WO2022079446A1 (en) 2020-10-15 2022-04-21 Kalvista Pharmaceuticals Limited Treatments of angioedema
EP4232031A1 (en) 2020-10-23 2023-08-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
WO2022172006A1 (en) 2021-02-09 2022-08-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023209381A1 (en) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2964956D1 (en) * 1978-07-18 1983-04-07 Kabi Ab Bradykinin inhibiting tripeptide derivatives, process for their preparation and pharmaceutical preparations containing them
US4563305A (en) * 1981-01-07 1986-01-07 University Of Miami Radiolabelled substrates for assaying mammalian enzymes
US4835253A (en) * 1987-04-03 1989-05-30 The University Hospital Specific inhibitors of tissue kallikrein
ZA897515B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors

Also Published As

Publication number Publication date
NO930731D0 (en) 1993-02-26
AU8438791A (en) 1992-03-30
CA2090858A1 (en) 1992-03-08
FI930946A0 (en) 1993-03-03
HU9300610D0 (en) 1993-05-28
FI930946A (en) 1993-04-26
PT98885A (en) 1992-08-31
EP0652893A1 (en) 1995-05-17
IE913120A1 (en) 1992-03-11
WO1992004371A1 (en) 1992-03-19
ZA917096B (en) 1992-04-29
GB9019558D0 (en) 1990-10-24
JPH06501461A (en) 1994-02-17
HUT64084A (en) 1993-11-29
MC2313A1 (en) 1993-09-27

Similar Documents

Publication Publication Date Title
NO930731L (en) kininogenase inhibitor
GB1586521A (en) Analgesic tetrapeptides and pentapeptides
US5484771A (en) Antiherpes peptide derivatives having a 1,4-dioxo-C, N-terminus
US4439360A (en) Retro-inverso analogues of C-terminal penta and hexapeptides of Substance P
AU5963290A (en) Inhibition of the n-end rule pathway in living cells
Ondetti Citrulline-containing analogs of bradykinin
WO1992017025A3 (en) GnRH analogs
EP0161007A2 (en) Retro - inverso C-Terminal hexapeptide analogues of substance P
US4104371A (en) Psychopharmacologically active peptides and peptide-derivatives, and the use thereof
KR840001668B1 (en) Process for the preparation of peptides
SG171348A1 (en) Tumor necrosis factor alpha inhibiting peptides and uses thereof
GB1584968A (en) Pentapeptides processes for their preparation and pharmaceutical compositions containing them
US4322342A (en) Analgesic compounds
US5700780A (en) Antiviral peptide derivatives having a 2-oxoalkyl amino acid side chain
Jarvis et al. Structure of the cell wall of Staphylococcus aureus. VIII. Structure and chemical synthesis of the basic peptides released by the Myxobacterium enzyme
US5312811A (en) Peptide derivatives and antidemetia agents
US3973006A (en) Peptide enzyme inhibitors of angiotensin I
Sugano et al. Studies of peptide antibiotics. XXX. Syntheses of gramicidin S analogs containing N-methylleucine in place of leucine
GB1587427A (en) Polypeptide derivatives
KR920701180A (en) 4H-3,1-benzoxazin-4-one compound and pharmaceutical composition for inhibiting elastase thereof
US3268502A (en) Undecapeptides
WO1988005049A1 (en) Novel compounds
US4087419A (en) Heptapeptides and methods for their production
Byk et al. Synthesis and conformational analysis of peptide inhibitors of farnesyltransferase
HU181402B (en) Process for preparing new peptides with psychopharmacological activity